Role of Adenosine and Nitric Oxide on the Mechanisms of Action of Dipyridamole
- 1 October 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 36 (10) , 2170-2175
Abstract
Background and Purpose— The combination of dipyridamole and aspirin has been shown to be more effective than aspirin alone in the secondary prevention of stroke. Dipyridamole may act by inhibiting adenosine uptake, thus potentiating its actions. Dipyridamole also inhibits cGMP-specific phosphodiesterases (PDE) and, through this mechanism, could potentiate cGMP-mediated actions of nitric oxide. Methods— To define the mechanism of action of dipyridamole, we studied the local vascular effects of adenosine, acetylcholine (NO-mediated dilation), and nitroprusside (cGMP-mediated dilation) in a double-blind study after treatment with dipyridamole/aspirin (200 mg dipyridamole/25 mg aspirin twice a day) or aspirin control for 7 days in 6 normal volunteers. Vasodilators were administered into the brachial artery in the nondominant arm in random order and forearm blood flow (FBF) was measured by venous occlusion plethysmography. Results— Adenosine at a dosage of 125 μg/min increased FBF from 4.6±0.9 to 29.4±5.3 (539% increase) with dipyridamole/aspirin and from 3.9±0.8 to 12±2.5 mL/100 mL forearm/min (208% increase) with aspirin alone ( P =0.007). In contrast, dipyridamole/aspirin did not alter the response to acetylcholine or to nitroprusside. The magnitude of adenosine-induced vasodilation correlated with plasma dipyridamole concentrations ( r 2 =0.6); no correlation was observed with acetylcholine- or nitroprusside-induced vasodilation. Similar potentiation of adenosine, but not acetylcholine or nitroprusside, was observed in 7 additional subjects when adenosine, acetylcholine, and nitroprusside were given in random order before and 2 hours after a single dose of dipyridamole/aspirin. Conclusion— The effects of dipyridamole on resistance vessels are preferentially explained by potentiation of adenosine mechanisms rather than potentiation of nitric oxide or other cGMP-mediated actions.Keywords
This publication has 26 references indexed in Scilit:
- Thrombolysis Beyond the GuidelinesStroke, 2005
- The Effect of Circulating Adenosine on Cerebral Haemodynamics and Headache Generation in Healthy SubjectsCephalalgia, 2005
- Ongoing and Planned Trials of Antiplatelet Therapy in the Acute and Long-Term Management of Patients with Ischaemic Brain Syndromes: Setting a New Standard of CareCerebrovascular Diseases, 2004
- Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular DiseaseStroke, 2003
- Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human PlateletsStroke, 2003
- Cyclic nucleotide phosphodiesterasesJournal of Allergy and Clinical Immunology, 2001
- Cloning and Characterization of the Human and Mouse PDE7B, a Novel cAMP-Specific Cyclic Nucleotide PhosphodiesteraseBiochemical and Biophysical Research Communications, 2000
- Inhibition of Ecto-5′-nucleotidase by Nitric Oxide DonorsJournal of Biological Chemistry, 1996
- Inhibition of Nitric Oxide Limits Infarct Size in the in Situ Rabbit HeartBiochemical and Biophysical Research Communications, 1993
- Cardiovascular effects of adenosine infusion in man and their modulation by dipyridamoleLife Sciences, 1986